Company Immunovant, Inc. Nasdaq
Equities
US45258J2015
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Salzmann
CEO | Chief Executive Officer | 56 | 31/05/19 |
Eva Barnett
DFI | Director of Finance/CFO | 44 | 03/10/21 |
Sheetal Patel
CTO | Chief Tech/Sci/R&D Officer | - | - |
Ian Gourley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Maria Alba
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jennifer Moseley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 23/08/20 |
Jay Stout
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/03/23 |
Chief Tech/Sci/R&D Officer | 66 | 31/05/21 | |
Chau Cheng
IRC | Investor Relations Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 17/12/19 |
Andrew Fromkin
BRD | Director/Board Member | 58 | 17/12/19 |
Douglas Hughes
BRD | Director/Board Member | 62 | 17/12/19 |
Atul Pande
BRD | Director/Board Member | 69 | 17/12/19 |
Frank Torti
CHM | Chairman | 45 | 17/12/19 |
Eric Venker
BRD | Director/Board Member | 37 | 17/02/20 |
Peter Salzmann
CEO | Chief Executive Officer | 56 | 31/05/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 146,053,941 | 62,422,461 ( 42.74 %) | 0 | 42.74 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |